Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1132-8291 | Other Identifier | Universal Trial Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cystic fibrosis (CF) is an inherited disorder which results in increased thickness of secretions, especially in the lungs. By adulthood, the majority of patients with CF will have a bacteria living in their lungs, called Pseudomonas aeruginosa which can cause lung infections. This usually results in worsening respiratory symptoms and often an acute deterioration in their lung function. They are usually treated with antibiotics that target the Pseudomonas aeruginosa. These antibiotics are typically given as short intravenous infusions several times a day. This study aims to compare the standard method of giving these antibiotics with a different strategy of giving these antibiotics to see if this can improve the outcomes of treatment of these infections and reduce the amount of Pseudomonas aeruginosa in the lungs of these patients. This strategy consists of giving the same antibiotics continuously, to ensure there is always enough antibiotic in the bloodstream and the lung to be able to kill the bacteria.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intermittent, short infusion | Active Comparator | Infusion over 30 minutes of either: Cefepime 1g q8/24 OR Ceftazidime 2g q8/24 OR Meropenem 1g q8/24 OR Piperacillin-Tazobactam 4.5g q8/24 OR Ticarcillin-clavulanate 3.1g q6/24 Antibiotic chosen by treating physician |
|
| Continuous infusion | Experimental | Continuous infusion of either: Cefepime 1.5g over 12h, q12/24 after initial loading dose of 500mg OR Ceftazidime 3g over 12h, q12/24 after initial loading dose 1g OR Meropenem 1.5g over 12h, q12/24 after initial loading dose 500mg OR Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g OR Ticarcillin-clavulanate 12.4g over 24h after initial loading dose 1.55g Antibiotic chosen by treating physician |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intermittent, short infusion Ceftazidime | Drug | Ceftazidime 1g q8/24 |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Cystic Fibrosis Questionnaire-Revised respiratory component (CFQ-R) respiratory symptom score | Day 0 to Day 14 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory symptom score | Day 0 to Day 7, Day 0 to Day 28 | |
| Lung function testing; Forced volume expired in one second (FEV1) | Day 0 to Day 7, Day 0 to Day 28 |
Not provided
Inclusion Criteria:
Patients >= 18 years of age,
Pseudomonas aeruginosa isolated in sputum within the last 12 months,
has an acute infective exacerbation, defined by international standards of 2 or more of the following in the last 2 weeks:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anton Peleg, MBBS, FRACP. | The Alfred | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Alfred Hospital | Melbourne | Victoria | 3181 | Australia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Continuous infusion Ceftazidime |
| Drug |
Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24 |
|
| Intermittent, short infusion Meropenem | Drug | Meropenem 1g q8/24, infusion over 30 minutes |
|
| Continuous infusion Meropenem | Drug | Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24 |
|
| Intermittent, short infusion Ticarcillin-clavulanate | Drug | Ticarcillin/clavulanate 3.1g q6/24 |
|
| Continuous infusion Ticarcillin-clavulanate | Drug | Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24 |
|
| Intermittent, short infusion Cefepime | Drug | Cefepime 1g q8/24 |
|
| Continuous infusion Cefepime | Drug | Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24 |
|
| Continuous infusion Piperacillin tazobactam | Drug | Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24 |
|
| Intermittent, short infusion Piperacillin tazobactam | Drug | Piperacillin tazobactam 4.5g q6/24 |
|
| C-reactive peptide (CRP) | Day 0 to Day 3 |
| Quantitative bacterial load in sputum (total + Pseudomonas aeruginosa) | Measured by PCR. | Day 0 to Day 3, Day 0 to Day 7 |
| Time above minimum inhibitory concentration (MIC) | Day 3 |
| Antibiotic stability | For ceftazidime and meropenem, antibiotic levels will be measured from the infusion bag at the beginning and end of the infusion to determine the amount of degradation of these antibiotics. The temperature of the infusion bags will be monitored continuously during this time. | Day 3 |
| Pseudomonas aeruginosa virulence gene determinants | A panel of different previously identified virulence gene determinants for Pseudomonas aeruginosa will be measured by RNA analysis. | Day 0 to Day 3 and Day 0 to Day 7 |
| ID | Term |
|---|---|
| D003550 | Cystic Fibrosis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007232 | Infant, Newborn, Diseases |
Not provided
Not provided